This week, Durig Capital looks to the healthcare sector where a specialty pharmaceutical company has posted solid back-to-back quarters resulting in increased guidance for 2018. As a result of Mallinckrodt Pharmaceuticals’ performance in both Q1 and Q2, company management has raised 2018 guidance citing solid performance across its product lines. Some of the highlights from Mallinckrodt’s Q2 numbers include:
Q2 cash flows from operating activities grew by 17.6% over the same period last year.
Net sales increased 5.3% year-over-year.
Adjusted Gross Profit increased by 8.4%
Year-to-date debt reduction of $535.2 million
Interest coverage over 2x for the first six months of 2018.